BioCryst Pharmaceuticals
BCRX
$6.33
Share price
-0.47%
Change (1 day)
-27.82%
Change (1 year)
Categories
Market capitalization of BioCryst Pharmaceuticals (BCRX)
Market cap: $1.30 Billion
As of May 2024 BioCryst Pharmaceuticals has a market cap of $1.30 Billion. This makes BioCryst Pharmaceuticals the world's 4837th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of BioCryst Pharmaceuticals from 2001 to 2024
End of year Market Cap
| Year | Market cap | Change |
|---|---|---|
| 2024 | $1.30 B | 6.49% |
| 2023 | $1.22 B | -42.68% |
| 2022 | $2.14 B | -14.12% |
| 2021 | $2.49 B | 89.45% |
| 2020 | $1.31 B | 147.45% |
| 2019 | $0.53 B | -40.15% |
| 2018 | $0.88 B | 83.83% |
| 2017 | $0.48 B | 3.49% |
| 2016 | $0.46 B | -38.33% |
| 2015 | $0.75 B | -13.48% |
| 2014 | $0.87 B | 94.83% |
| 2013 | $0.44 B | 521.44% |
| 2012 | $72.26 M | -35.29% |
| 2011 | $0.11 B | -51.95% |
| 2010 | $0.23 B | -18.05% |
| 2009 | $0.28 B | 441.16% |
| 2008 | $52.41 M | -77.66% |
| 2007 | $0.23 B | -30.6% |
| 2006 | $0.33 B | -29.94% |
| 2005 | $0.48 B | 283.76% |
| 2004 | $0.12 B | 2.73% |
| 2003 | $0.12 B | 622.2% |
| 2002 | $16.95 M | -75.69% |
| 2001 | $69.72 M |
End of Day market cap according to different sources
On May 15th, 2024 the market cap of BioCryst Pharmaceuticals was reported to be:
$1.37 Billion
$1.37 Billion
$1.31 Billion
$1.31 Billion
Market capitalization for similar companies or competitors
| Name | Market cap | Market cap differencediff. | Country |
|---|---|---|---|
 Gilead Sciences GILD | $83.37 B | 6,282.00% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $93.06 B | 7,024.25% | 🇬🇧 UK |
 Sarepta Therapeutics
SRPT | $12.30 B | 841.93% | 🇺🇸 USA |
 Repligen
RGEN | $9.77 B | 648.04% | 🇺🇸 USA |
 Novavax NVAX | $1.81 B | 38.90% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | $2.61 B | 100.10% | 🇺🇸 USA |
 NanoViricides NNVC | $22.96 M | -98.24% | 🇺🇸 USA |
 Cel-Sci
CVM | $76.65 M | -94.13% | 🇺🇸 USA |
 Emergent BioSolutions
EBS | $0.29 B | -77.26% | 🇺🇸 USA |